ICLR
ICON Public Limited Company · Healthcare · Medical - Diagnostics & Research
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 113 | +2 | 54.25M | $9.34B | +10 | −7 |
| Q1 2026 | 112 | -7 | 49.87M | $5.61B | +7 | −15 |
| Q4 2025 | 119 | -2 | 53.17M | $9.70B | +2 | −3 |
| Q3 2025 | 18 | -1 | 14.11M | $2.47B | +2 | −4 |
| Q2 2025 | 17 | +3 | 17.03M | $2.48B | +3 | — |
| Q1 2025 | 11 | -1 | 10.01M | $1.75B | +1 | −2 |
| Q4 2024 | 12 | -1 | 9.48M | $1.99B | +2 | −3 |
| Q3 2024 | 12 | -1 | 9.43M | $2.71B | +1 | −2 |
| Q2 2024 | 13 | — | 9.47M | $2.97B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 2.76M | — | $865.06M | 0.2% | n/c | 1 | SEC ↗ ×9 |
| 2 | T. Rowe Price ✦ | 2.62M | — | $821.00M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 3 | Citadel Advisors ✦ | 1.36M | — | $426.38M | 0.4% | n/c | 1 | SEC ↗ ×2 |
| 4 | Norges Bank ✦ (passive) | 969.89K | — | $304.03M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Millennium Management ✦ | 865.36K | — | $271.26M | 0.2% | n/c | 1 | SEC ↗ |
| 6 | Point72 Asset Management ✦ | 447.33K | — | $140.23M | 0.5% | n/c | 1 | SEC ↗ |
| 7 | Renaissance Technologies ✦ | 226.00K | — | $70.84M | 0.1% | n/c | 1 | SEC ↗ |
| 8 | Geode Capital Management ✦ (passive) | 82.71K | — | $25.93M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | D. E. Shaw & Co. ✦ | 79.74K | — | $25.00M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 10 | Arrowstreet Capital ✦ | 40.93K | — | $12.83M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Adage Capital Partners ✦ | 11.00K | — | $3.45M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Fisher Asset Management ✦ | 5.42K | — | $1.70M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 1.75K | — | $547,945 | 0.0% | n/c | 1 | SEC ↗ ×3 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 414 holders, 78.10M shares, $8.66B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 3.25K sh · $569,625
Director · 5.00K sh · $875,875
Director · 5.00K sh · $875,875
Officer · 259 sh · $42,416
Officer · 1.59K sh · $261,672
Officer · 180 sh · $29,792
Director · 87 sh · $14,157
Director · 97 sh · $15,886
Director · 590 sh · $97,037
Director · 67 sh · $11,089
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology